Safety of concomitant treatment with Non-Vitamin K Oral Anticoagulants and SSRI/SNRI antidepressants

Open access

Abstract

Introduction: Warfarin has been considered as a “gold standard” in the prevention and treatment of thromboembolic events since 1954. Since the introduction of direct oral anticoagulants in the last few years (NOAC-Non-Vitamin K antagonist Oral Anticoagulants) prescriptions volume for apixaban, edoxaban, dabigatran and rivaroxaban have been gradually surpassing warfarin. The benefits include: anticoagulation from day one, fixed daily dosing, elimination for the need of international normalised ratio (INR) monitoring, fewer interactions with food and co-administered medicines with reduced risk of bleeding and better overall life quality.

Objectives: Assessing evidence for the safe use of Non-vitamin K Oral Anticoagulants (NOAC) with Selective Serotonin Reuptake Inhibitors (SSRI) and Serotonin and Noradrenaline Reuptake Inhibitors (SNRI).

Method: Review of literature published between 2014 and 2016 was made using the key words: Selective Serotonin Reuptake Inhibitor, Serotonin and Noradrenaline Reuptake Inhibitors, apixaban, dabigatran, edoxaban, rivaroxaban, bleeding, interaction, depression with time description from 2014 to 2018. Evidence within the literature was then compared with guidelines from the National Institute for Health and Care Excellence (UK), British National Formulary (UK), Clinical Excellence Commission (Australia), Thrombophilia and Anticoagulation Clinic (USA) and Summaries of Product Characteristics (SPC).

Results: 1. Serotonin plays a critical role in maintaining homeostasis. Use of SSRI/SNRI compromises its platelet reuptake increasing risk of bleeding. 2. Increased tolerability and safety of NOAC over Warfarin, although caution is advised when NOAC is used with SSRI/SNRI with less evidence suggesting pharmacodynamic interactions. 3. It is not recommended to use NOAC with strong CYP and P-gp inhibitors.

Conclusions: With limited literature evidence, caution is advised when co-prescribed NOACs with SSRI/SNRI, especially with other cofactors and interacting medicines further increasing risk of bleeding.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Barr D Epps QJ. Direct oral anticoagulants: a review of common medication errors. J Thromb Thrombolysis. 2019; 47(1):146-154.

  • 2. Is there an interaction between warfarin and proton pump inhibitors? [Cited 13.01.2019]. Accessible at: https://www.sps.nhs.uk/wpcontent/uploads/2017/02/UKMI_QA_WarfarinPPI_Sept_2017.docx

  • 3. Wang Y Bajorek B. New oral anticoagulants in practice: pharmacological and practical considerations. Am J Cardiovasc Drugs. 2014; 14(3):175-89.

  • 4. Ingrasciotta Y Crisafulli S Pizzimenti V Marcianò I Mancuso A Andò G et al. Pharmacokinetics of new oral anticoagulants: implications for use in routine care. Expert Opin Drug Metab Toxicol. 2018; 14:1057-1069.

  • 5. Dexxience [EU]. BevyxXa [US] · Venous thromboemolism (VTE) prevention - first line - in at risk adult patients hospitalised for an acute medical illness [Cited 13.01.2019]. Accessible at: https://www.sps.nhs.uk/medicines/betrixaban/

  • 6. Gelosa P Castiglioni L Tenconi M Baldessin L Racagni G Corsini A et al. Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs). Pharmacol Res. 2018; 135:60-79.

  • 7. ELIQUIS INN-apixaban. Aneks I Charakterystyka produktu leczniczego. [Cited 03.01.2019]. Accessible at: http://leki.urpl.gov.pl/files/16_Eliquis.pdf

  • 8. Pradaxa INN-dabigatran etexilate. Aneks I Charakterystyka produktu leczniczego [Cited 03.01.2019]. Accessible at: http://leki.urpl.gov.pl/files/25_PRADAXA_kap_tw.pdf

  • 9. Lixiana INN-edoxaban. Aneks I Charakterystyka produktu leczniczego. [Cited 03.01.2019]. Accessible at: http://ec.europa.eu/health/documents/community-register/2015/20150619132091/anx_132091_pl.pdf

  • 10. Xarelto INN-rivaroxaban. Aneks I Charakterystyka produktu leczniczego. [Cited 03.01.2019]. Accessible at: http://leki.urpl.gov.pl/files/Xarelto.pdf

  • 11. Paradise HT Berlowitz DR Ozonoff A Miller DR Hylek EM Ash AS et al. Outcomes of anticoagulation therapy in patients with mental health conditions. J Gen Intern Med. 2014; 29(6):855-61.

  • 12. Michal M Prochaska JH Keller K Göbel S Coldewey M Ullmann A et al. Symptoms of depression and anxiety predict mortality in patients undergoing oral anticoagulation: Results from the thrombEVAL study program. Int J Cardiol. 2015; 187:614-9

  • 13. José F Nasser N Almeida MM Silva LS Almeida RGP et al. Psychiatric disorders and cardiovascular system: heart-brain interaction. Int J Cardiovasc Sci. 2016; 29(1): 65-75.

  • 14. Low Y Setia S Lima G. Drug-drug interactions involving antidepressants: focus on desvenlafaxine. Neuropsychiatr Dis Treat. 2018; 14:567-580.

  • 15. Browne JA Sandberg BF D’Apuzzo MR Novicoff WM. Depression Is Associated With Early Postoperative Outcomes Following Total Joint Arthroplasty. J Arthroplasty. 201; 29(3):481-3.

  • 16. Hackett ML Pickles K. Part I: frequency of depression after stroke: an updated systematic review and meta-analysis of observational studies. Int J Stroke. 2014; 9(8):1017-25.

  • 17. Jennum P Baandrup L Iversen HK Ibsen R Kjellberg J. Mortality and use of psychotropic medication in patients with stroke: a population-wide register-based study. BMJ Open. 2016; 6(3):e010662.

  • 18. NOACs and Antidepressants - What are the risks of using these together and how should these risks be managed? [Cited 04.01.2019]. Accessible at: https://www.sps.nhs.uk/wp-content/uploads/2018/07/SW_QA_225.2_NOACS_Antidepress_-Final.docx

  • 19. Yano JM Yu K Donaldson GP Shastri GG Ann P Ma L et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. 2015; 161(2):264-76.

  • 20. Steffel J Verhamme P Potpara TS Albaladejo P Antz M Desteghe L et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018; 39(16):1330-1393.

  • 21. Palleria C Di Paolo A Giofrè C Caglioti C Leuzzi G Siniscalchi A et al. Pharmacokinetic drug-drug interaction and their implication in clinical management. J Res Med Sci. 2013; 18(7):601-10.

  • 22. Kennedy C Brewer L Williams D. Drug interactions. Medicine. 2016; 44(7): 422–426.

  • 23. Zanger UM Raimundo S Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology genetics biochemistry. Naunyn Schmiedebergs Arch Pharmacol. 2004; 369(1):23-37.

  • 24. Scheen AJ. Cytochrome P450-mediated cardiovascular drug interactions. Expert Opin Drug Metab Toxicol. 2011; 7(9):1065-82.

  • 25. Mulder H Heerdink ER van Iersel EE Wilmink FW Egberts AC. Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross-sectional study. Ann Pharmacother. 2007; 41(3): 408-13.

  • 26. Silva R Vilas-Boas V Carmo H Dinis-Oliveira RJ Carvalho F de Lourdes Bastos M et al. Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy. Pharmacol Ther. 2015; 149:1-123.

  • 27. PRAM INN-citalopram. Charakterystyka produktu leczniczego. (Cited 19.01.2019). Accessible at: http://chpl.com.pl/data_files/2013-09-18_pl-smpc-pram-17.09.2013_clean.pdf

  • 28. Escitalopram Actavis INN-escitalopram. Charakterystyka produktu leczniczego. (Cited 19.01.2019). Accessible at: http://chpl.com.pl/data_files/2013-08-21_escitalopram_actavis_chpl_wspolna_v014_czerwiec_2013_.pdf

  • 29. PROZAC INN-fluoxetine. Summary of Product Characteristics (SPC). (Cited 15.01.2019). Accessible at: https://www.medicines.org.uk/emc/product/3768/smpc

  • 30. Fevarin INN-fluwoksamina. Charakterystyka produktu leczniczego. (Cited 05.01.2019). Accessible at: https://pub.rejestrymedyczne.csioz.gov.pl/Pobieranie.ashx?type=2419-c

  • 31. Sertraline. Summary of Product Characteristics (SPC). (Cited 05.01.2019) Accessible at: https://www.medicines.org.uk/emc/product/3501/smpc

  • 32. Joint Formulary Committee (September 2018-March 2019). British National Formulary. 76th edition. London: British Medical Association and Royal Pharmaceutical Society of Great Britain. Appendix 1 Interactions 1264.

  • 33. BNF & BNFC App. BNF Publications- British National Formulary. (Cited 05.01.2018). Accessible at: https://www.bnf.org/products/bnfbnfcapp/

  • 34. Clinical Excellence Commission 2017 Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Guidelines Updated July 2017.Sydney: Clinical Excellence Commission.

  • 35. Thrombophilia and Anticoagulation Clinic Minneapolis Heart Institute® Abbott Northwestern Hospital. Reviewed August 2016.

  • 36. Giugliano RP Ruff CT Braunwald E Murphy SA Wiviott SD Halperin JL et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369(22):2093-104.

  • 37. Forbes HL Polasek TM. Potential drug-drug interactions with direct oral anticoagulants in elderly hospitalized patients. Ther Adv Drug Saf. 2017; 8(10):319-328.

  • 38. Aguiar CCT. Treatment of Depression in Patients on Anticoagulation Therapy: Antidepressant-Rivaroxaban Drug Interactions. J Drug Metab Toxicol. 2016; 7:215.

  • 39. Caughey GE Kalisch Ellett LM Barratt JD Shakib S. Apixaban concomitant medicines and spontaneous reports of haemorrhagic events. Ther Adv Drug Saf. 2017; 8(5):157-164.

  • 40. Stöllberger C. Drug interactions with new oral anticoagulants in elderly patients. Expert Rev Clin Pharmacol. 2017; 10(11):1191-1202.

Search
Journal information
Metrics
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 484 484 22
PDF Downloads 215 215 29